Barclays PLC Buys 100,678 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Barclays PLC boosted its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 352.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 129,210 shares of the company's stock after buying an additional 100,678 shares during the quarter. Barclays PLC owned approximately 0.08% of Neumora Therapeutics worth $1,708,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of NMRA. Bank of New York Mellon Corp raised its holdings in shares of Neumora Therapeutics by 474.1% in the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock valued at $2,316,000 after purchasing an additional 194,559 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Neumora Therapeutics in the 2nd quarter worth about $166,000. Rhumbline Advisers increased its stake in Neumora Therapeutics by 488.3% in the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company's stock valued at $1,015,000 after buying an additional 85,706 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Neumora Therapeutics by 31.6% in the second quarter. TD Asset Management Inc now owns 144,994 shares of the company's stock valued at $1,425,000 after acquiring an additional 34,800 shares in the last quarter. Finally, Amalgamated Bank increased its position in shares of Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock valued at $29,000 after acquiring an additional 2,402 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert A. Lenz sold 5,563 shares of the company's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares in the company, valued at approximately $4,847,719.66. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Neumora Therapeutics Stock Performance

NASDAQ NMRA traded down $0.01 during trading on Friday, hitting $11.33. 936,490 shares of the company's stock traded hands, compared to its average volume of 750,777. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -6.06 and a beta of 3.34. The business has a 50 day moving average of $11.07 and a 200-day moving average of $11.58. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same quarter in the prior year, the firm posted ($1.14) EPS. On average, analysts expect that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

NMRA has been the topic of several research analyst reports. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research note on Monday, December 16th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Neumora Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $23.40.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.